Indication

In infants and children from 1 month to less than 7 years of age for:

  • treatment in monotherapy of infantile spasms (West's syndrome)

  • treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

Medicine details

Medicine name:
vigabatrin (Kigabeq)
SMC ID:
SMC2352
Pharmaceutical company
Veriton Pharma
BNF chapter
Central nervous system
Submission type
Abbreviated
Publication due date:
14 June 2021